Nan Hu

1.3k total citations · 1 hit paper
45 papers, 584 citations indexed

About

Nan Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Nan Hu has authored 45 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Nan Hu's work include Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Occupational and environmental lung diseases (4 papers). Nan Hu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Occupational and environmental lung diseases (4 papers). Nan Hu collaborates with scholars based in China, United States and Japan. Nan Hu's co-authors include Sonja P. Dawsey, Miriam R. Anver, Mark J. Roth, D Ratnasinghe, Philip R. Taylor, Joseph A. Tangrea, David Balli, Robin Cornelissen, Solange Peters and Sanjay Popat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Nan Hu

39 papers receiving 577 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

2022 158 citations Solange Peters, Arnaud Scherpereel et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Nan Hu

Since Specialization

Citations

This map shows the geographic impact of Nan Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Hu more than expected).

Fields of papers citing papers by Nan Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Hu. The network helps show where Nan Hu may publish in the future.

Co-authorship network of co-authors of Nan Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Nan Hu. A scholar is included among the top collaborators of Nan Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan Hu. Nan Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 2026 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Anne S. Tsao, (unknown), (unknown), (unknown), (unknown), (unknown), Toby Talbot, (unknown), Dariusz M. Kowalski, (unknown), (unknown), (unknown), Nan Hu, (unknown), (unknown), Yu-Han Hung, (unknown)	0
2	Self‐Optimized Reconstruction of Metal–Organic Frameworks Introduces Cation Vacancies for Selective Electrosynthesis of Hydrogen Peroxide 2025 ·Angewandte Chemie ·Chao Miao, (unknown), Ziwen An, Xun Pan, Yanbo Li, Nan Hu, Lina Li, Yongxin Zhou, Guohua Zhao	1
3	Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. 2025 ·Journal of Clinical Oncology ·Masatoshi Kudo, Thomas Yau, Thomas Decaens, Bruno Sangro, (unknown), Leonardo Gomes da Fonseca, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Nan Hu, (unknown), (unknown), Peter R. Galle	2
4	398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648 2024 ·Annals of Oncology ·(unknown), Ian Chau, Jaffer A. Ajani, Yuko Kitagawa, (unknown), Lucjan Wyrwicz, (unknown), Takashi Ogata, (unknown), (unknown), (unknown), Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Mariela Blum Murphy, (unknown), Nan Hu, Yasuhiro Matsumura, Koji Kato, Y. Doki	0
5	Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648. 2024 ·Journal of Clinical Oncology ·Ian Chau, Jaffer A. Ajani, Yuko Kitagawa, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Raheel Nathani, Nan Hu, Yasuhiro Matsumura, (unknown), Yuichiro� Doki	0
6	Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. 2024 ·Journal of Clinical Oncology ·Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker, Stéphanie Bordenave-Juchereau, Manuel Cobo, Óscar Juan, Niels Reinmuth, Eduardo Richardet, Enriqueta Felip, J. Menezes, Ying Cheng, Hideaki Mizutani, David P. Carbone, Shun Lü, Thomas John, (unknown), Javed Mahmood, Nan Hu, Laura J. Eccles, Luis Paz‐Ares	6
7	Role of AhR-Hsp90-MDM2-mediated VDR ubiquitination in PM2.5-induced renal toxicity 2024 ·Environmental Research ·Peng Zhang, Lei Wang, Jing Zhang, Qi An, (unknown), Nan Hu, (unknown), Lan He, (unknown)	2
8	1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial 2023 ·Annals of Oncology ·Mark M. Awad, Patrick M. Forde, Nicolas Girard, (unknown), (unknown), Shun Lü, (unknown), Enriqueta Felip, Stephen Broderick, Scott J. Swanson, (unknown), Keith M. Kerr, (unknown), (unknown), (unknown), Javed Mahmood, (unknown), David Balli, Nan Hu, Mariano Provencio	14
9	Differentiation Between Amyotrophic Lateral Sclerosis and Mimics Using Quantitative Analysis of Fasciculation with Muscle Ultrasound 2023 ·Chinese Medical Sciences Journal ·Jing Fang, Yi Li, Jingwen Niu, Nan Hu, Yuzhou Guan, Liying Cui, (unknown)	2
10	Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs). 2023 ·Journal of Clinical Oncology ·(unknown), Xianyun Wang, Yixun Liu, (unknown), Yiqun Zhang, Xiaohui Wang, Nan Hu, Chunyan Yang, Xiaohong Duan, Zhihua Pei, Dongliang Wang, Qiming Zhou	1
11	LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743 2022 ·Annals of Oncology ·Gérard Zalcman, (unknown), Robin Cornelissen, Laurent Greillier, (unknown), Julien Mazières, Peter Briggs, Anna K. Nowak, Anne S. Tsao, (unknown), Solange Peters, Aaron S. Mansfield, Sanjay Popat, (unknown), Judith Bushong, Nan Hu, Thomas Spires, David Balli, Laura J. Eccles, Paul Baas	5
12	Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting 2022 ·BMC Medical Research Methodology ·Rong Chen, (unknown), J. Lister, Rong Han, Nan Hu, (unknown), Alexander Solms, (unknown), Jamie O’Hara, Shanlian Hu	0
13	Case Report: Endocapillary Glomerulopathy Associated With Large Granular T Lymphocyte Leukemia 2022 ·Frontiers in Immunology ·Tao Zhao, Nan Hu, Xiaojuan Yu, Tao Su	3
14	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 breakdown → 2022 ·Annals of Oncology ·Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, Thomas Talbot, I. Monnet, Sandrine Hiret, Paul Baas, Anna K. Nowak, Nobukazu Fujimoto, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, (unknown), Nan Hu, David Balli, Thomas Spires, Gérard Zalcman	158
15	122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 2021 ·Annals of Oncology ·Martin Reck, Tudor–Eliade Ciuleanu, Adam Płużański, (unknown), Reyes Bernabé, Helena Linardou, (unknown), Carlos Gallardo, Makoto Nishio, Solange Peters, Luis Paz‐Ares, Matthew D. Hellmann, Hossein Borghaei, Suresh S. Ramalingam, Kenneth J. O’Byrne, Nan Hu, Judith Bushong, Laura J. Eccles, Diederik J. Grootendorst, Julie R. Brahmer	5
16	Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review 2021 ·Orphanet Journal of Rare Diseases ·(unknown), Xuan Zhou, Nan Hu	7
17	An electrospun fiber-covered stent with programmable dual drug release for endothelialization acceleration and lumen stenosis prevention 2019 ·Acta Biomaterialia ·Yiran Zhang, (unknown), Junyuan Xiao, (unknown), Nan Hu, Ming‐Hua Li, Lianfu Deng, Ying-Sheng Cheng, Yueqi Zhu, Wenguo Cui	51
18	Propofol Protects Rat Cardiomyocytes from Anthracycline‐Induced Apoptosis by Regulating MicroRNA‐181a In Vitro and In Vivo 2018 ·Oxidative Medicine and Cellular Longevity ·Hongwei Zhao, Xiaobei Zhang, Ying Zheng, (unknown), Xiaokun Wang, Nan Hu, Peng Zhou, Kaiyuan Wang	14
19	Protective role of astragalus injection in spinal cord ischemia-reperfusion injury in rats 2018 ·Neurosciences ·(unknown), Zhenfei Song, (unknown), (unknown), Nan Hu, Yong Hu, (unknown)	9
20	The Genetic Variation of ARRB2 is Associated with Late-onset Alzheimer's Disease in Han Chinese 2014 ·Current Alzheimer Research ·Teng Jiang, Jin‐Tai Yu, Yingli Wang, Hui-Fu Wang, Wei Zhang, Nan Hu, Lin Tan, Lei Sun, Meng‐Shan Tan, Xi‐Chen Zhu, Lan Tan	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact